Idéal Investisseur
Français English
CAC 40 : Market closed
8 218,24 pts
-0.32%


Last updated : 05/06/2026 - 17h29 (last close)
Last close data
🏠 Home   ➤    Stock news

Bastide Completes the Sale of Experf to Italian Group Sapio

On Monday, Bastide Group announced the completion of the sale of its subsidiary New Medical Concept, the holding company of Experf Group (home infusion and nutrition), to the Italian group Sapio. The agreement signed on May 21 lifted all its suspensive conditions at the end of the month.


Bastide Completes the Sale of Experf to Italian Group Sapio

A Divestiture to Focus Resources

The finalization of this divestiture is part of a restructuring of Bastide Group's portfolio of activities. The operation is in line with the company's desire to focus its resources on areas considered most strategic and with higher added value, according to the press release. Vincent Bastide, CEO of the group, believes that this sale allows to 'crystallize the value created since the integration of Experf into the group' and to 'strengthen our financial structure'.

Sapio Strengthens Its Presence in France

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

For Sapio Group, this acquisition is a key step in its European expansion strategy. The Italian multinational, present in industrial and medical gases and home care services, plans to leverage Experf's territorial network in France to continue its growth in the home health services sector. Its presence in France will reach more than 140 million euros in revenue through this operation, complementing its existing structures Homeperf, Synapse Santé, and Synartis. According to the source, Sapio's total revenue is expected to exceed 1 billion euros once the acquisition is completed.



Sector Santé · Dispositifs médicaux Services de santé


Assurance vie

Context

Period
  • Period: 9M2025/2026
Key reported figures
  • Revenue: 391.9M€
Guidance from the release
  • Bonne dynamique sur les 9 premiers mois de l'exercice.
Risks mentioned
  • dégradation de l'activité liée à la réforme VPH
  • impact du ralentissement au Maintien à Domicile
Opportunities identified
  • dynamique soutenue des Prestations de santé à domicile
  • contribution exceptionnelle de certains contrats en collectivités

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit